DIMINOR 2.36 GM

Indications

• Muscle spasticity
• Muscle spasms
• Pain management in musculoskeletal disorders

Dosage

Children: Refer to specific pediatric guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to specific clinical guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

Diaceturate acts by inhibiting the presynaptic release of acetylcholine at the neuromuscular junction, thereby reducing muscle contraction. This inhibition leads to decreased excitability of motor neurons and relaxation of skeletal muscles.

Pharmacodynamics

The pharmacodynamic profile of diaceturate indicates its ability to produce muscle relaxation through central and peripheral mechanisms. It alters neurotransmitter release and modulates synaptic transmission, leading to decreased muscle tone and increased ease of movement. Its effects can be observed within a short time frame following administration, making it effective for acute muscle spasm relief.

Pharmacokinetics

Diaceturate is typically absorbed rapidly after administration, with peak plasma concentrations achieved within a few hours. It undergoes hepatic metabolism, with its metabolites being excreted primarily through the kidneys. The drug has a relatively short half-life, necessitating multiple doses for sustained effect in clinical use.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Dizziness
• Rash

Precautions

• Use with caution in patients with liver impairment
• Monitor for allergic reactions
• Caution in patients with renal impairment

Pregnancy

The safety of diaceturate during pregnancy has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when using diaceturate in breastfeeding women, as it's unknown if it passes into breast milk.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense
• African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei rhodesiense

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations in adults.

Mechanism of action

Diminazine acts by interacting with the DNA of the protozoan parasites, leading to an inhibition of nucleic acid synthesis. It is thought to inhibit mitochondrial functions, disrupting the energy metabolism of the parasites and ultimately leading to their death. The exact molecular pathways are not fully elucidated, but it is known to interfere with the parasite's ability to replicate and survive in the host.

Pharmacodynamics

Diminazine exhibits a dose-dependent effect on the parasites, leading to a reduction in parasitemia. The drug's effectiveness is enhanced in the early stages of infection, and resistance may develop with prolonged use. The clinical response is monitored through parasitological assessments and symptom resolution, with treatment typically administered in a controlled healthcare setting.

Pharmacokinetics

Diminazine is administered parenterally and is rapidly distributed in the body. It has a moderate volume of distribution and is metabolized in the liver, with renal excretion of its metabolites. The half-life of diminazine varies, generally ranging from 4 to 10 hours, depending on individual patient factors. Therapeutic drug monitoring may be employed to assess plasma concentrations and ensure efficacy while minimizing toxicity.

Pregnancy

Diminazine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether diminazine is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, protected from light.

Formulations

• {'name': 'Diminazine Aceturate', 'type': 'Injection', 'strength': '100 mg/mL'}

Indications

• Facial volume loss
• Wrinkle reduction
• Lip enhancement
• Cheek augmentation
• Nasal contouring
• Reconstructive procedures

Dosage

Children: The use of fillers in paediatric populations is not well established and typically not recommended. Consult a specialist for any potential use in children.

Adults: Dosage varies based on the specific filler used, the area being treated, and the desired outcome. Refer to the manufacturer's guidelines and consult with a qualified healthcare provider for specific dosing recommendations.

Mechanism of action

Fillers work by physically occupying space within the dermal layer of the skin, providing volume and support. Hyaluronic acid, for instance, attracts and retains water, enhancing tissue hydration and plumpness. Collagen-based fillers stimulate collagen production in the body, which can improve skin elasticity and texture over time.

Pharmacodynamics

The pharmacodynamics of fillers is largely dependent on their composition. Hyaluronic acid fillers can provide immediate volume restoration and improve skin turgor. Collagen fillers may take time to integrate and stimulate the body’s own collagen production. The effects of fillers can last from several months to two years, depending on the type of filler used and the individual's metabolism and lifestyle.

Pharmacokinetics

The pharmacokinetics of fillers vary based on their composition. Hyaluronic acid fillers are gradually metabolized by hyaluronidase enzymes present in the body. Their absorption and degradation rates can be influenced by factors such as the injection technique and the area treated. Collagen fillers may be broken down by collagenase enzymes, with varying durations of effect depending on the specific formulation and patient factors.

Pregnancy

Safety during pregnancy is not well established; consult a healthcare provider.

Breast-feeding

Safety during breastfeeding is not well established; consult a healthcare provider.

Storage

Store at room temperature, away from light and moisture.